NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits can be filed on behalf of shareholders of Enochian Biosciences, Inc. NOVWeber, Inc. WEBRCoinbase Global, Inc. COINand Fulgent Genetics, Inc. FLGT. Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

Enochian Biosciences, Inc. NOV

Class Period: January 17, 2018 – June 27, 2022

Lead Plaintiff Deadline: September 26, 2022

Enochian is a preclinical-stage biotechnology company purportedly discovering and developing pharmaceutical and biological products for the treatment of human immunodeficiency virus, hepatitis B virus, influenza and coronavirus infections, and cancer.

Enochian and its top management have recognized Serhat Gumrukcu (“Gumrukcu”), Enochian’s co-founder and largest shareholder, as the “genius” and “inventor” of the technology and science behind the Company’s product pipeline.

Enochian has multiple consulting and licensing agreements with G-Tech Bio, LLC, a California limited liability company (“G-Tech”), and the G Health Research Foundation, a California not-for-profit organization organized under the laws of California, doing business as Seraph Research Institute (“SRI”), both of which are controlled by Gumrukcu.

On May 25, 2022, the US Department of Justice announced that Gumrukcu had been arrested and charged with murder conspiracy.

As a result of this news, Enochian’s stock price fell $2.17 per share, or 36.97%, to close at $3.70 per share on May 25, 2022.

Then, on June 1, 2022, Hindenburg Research (“Hindenburg”) released a report on Enochian entitled “Miracle Cures and Murder For Hire: How A Spoon-Bending Turkish Magician Built A $600 Million Nasdaq-listed Scam Based On A Lifetime.” Of Lies” (the “Hindenburg Report”). The Hindenburg Report found that the person in…